Acquired defects in signalling pathways leading to programmed cell death (PCD) are among the major hallmarks of cancer. Although focus has been on caspasedependent apoptotic death pathways, evidence is now accumulating that nonapoptotic PCD also can form an important barrier against tumour initiation and progression. Akin to the earlier landmark discoveries that lead to the identification of the major cancer-related proteins like p53, c-Myc and Bcl-2 as controllers of spontaneous and therapy-induced apoptosis, numerous proteins with properties of tumour suppressors and oncoproteins have recently been identified as key regulators of alternative death programmes. The emerging data on the molecular mechanisms regulating nonapoptotic PCD may have potent therapeutic consequences.
Introduction
Cancer is a disease characterized by an imbalance between cell division and cell death (Hanahan and Weinberg, 2000) . Apoptosis is the best-defined cell death programme counteracting tumour growth. It is characterized by the activation of a specific family of cysteine proteases, the caspases, followed by a series of caspasemediated morphological changes such as the shrinkage of the cell, the condensation of the chromatin and the disintegration of the cell into small fragments that can be engulfed by nearby cells without inciting inflammation (Kerr et al., 1972; Strasser et al., 2000; Ferri and Kroemer, 2001; Kaufmann and Hengartner, 2001) . With respect to the ability of some cells to survive caspase activation, it would be dangerous for the organism to depend on a single protease family for the clearance of unwanted and potentially harmful cells . Indeed, accumulating data now show that programmed cell death (PCD) can occur in the complete absence of caspases, and evidence for death pathways where noncaspase proteases and other death effectors function as executioners is emerging (Ferri and Kroemer, 2001; Leist and Ja¨a¨ttela¨, 2001; Lockshin and Zakeri, 2002) . Experiments employing cancer cells with defective apoptosis machinery have revealed that most caspase-activating apoptotic stimuli, including oncogenes, p53, DNA-damaging drugs, proapoptotic Bcl-2 family members, cytotoxic lymphocytes and in some cases even death receptors, do not require known caspases for PCD to occur . Thus, in most death pathways the role of caspases is rather at the level of shaping the destruction of the cell that is already committed to die than at the level of the decision to die. In the following, I will first describe various types of PCD and their control at molecular and organelle level and then discuss the numerous links that connect transformation and tumour progression to the control of PCD.
Classification of PCD according to the nuclear morphology
The foremost criterion for PCD (or active cell death) that distinguishes it from accidental necrosis is the participation of active cellular processes that can be intercepted by interfering with intracellular signalling . The unclear definition of caspase-independent death pathways has been the major obstacle to their better understanding. Since the precise characterization of biochemical check points controlling caspase-independent PCD is still awaiting, the nuclear morphology of dying cells ) has been used as an alternative basis for the classification of PCD (Figure 1 ). According to the nuclear morphology, PCD can be divided into three subclasses: (i) classic apoptosis characterized by chromatin condensed to compact and almost geometric figures (stage 2 chromatin condensation), (ii) apoptosis-like PCD with less compact, lumpy chromatin masses (stage 1 chromatin condensation) and (iii) necrosis-like PCD that occurs either in the complete absence of chromatin condensation or at best with chromatin clustering to form loose speckles . So far, nearly all examples of classic apoptosis appear caspase dependent, caspases playing an active role in the activation of DNA fragmentation factor 45 (DFF45) that is responsible for the compact chromatin condensation (Sakahira et al., 1998) . Theoretically, stage 2 chromatin condensation could, however, occur caspase independently by endonuclease G (EndoG), a mitochondrial DNase that is released in response to various apoptotic stimuli (Li et al., 2001) . Most published forms of 'caspaseindependent apoptosis' fall into the category of apoptosis-like PCD even though some of the classic 'caspasedependent apoptosis' models also display this morphology, for example due to the lack of DFF45 expression. Apoptosis-inducing factor (AIF) released from the mitochondria during various forms of PCD (Susin et al., 1999) , calcium-regulated cytosolic cysteine proteases calpains, cathepsin B, a lysosomal cysteine protease that translocates into the cytosol and nucleus in response to many cellular stresses (Vancompernolle et al., 1998) , and L-DNase II derived from the leucocyte elastase inhibitor by post-translational modification induced by low pH or digestion with elastase (Torriglia et al., 1998) , are among the effector molecules that can trigger the stage 1 chromatin condensation. Autophagic degeneration (also called type II PCD) (Chi et al., 1999) and death receptor-induced necrosis (Vercammen et al., 1998a) lack chromatin condensation and can thus be classified as necrosis-like PCD. Owing to the enormous overlap and shared signalling pathways between the different death programmes, cells dying by apoptosisand necrosis-like PCD can display any degree and combination of other apoptotic features including phosphatidylserine exposure, cytoplasmic shrinkage, zeiosis, formation of apoptotic bodies, and even the activation of caspases . It should also be noted that a single stimulus often triggers several distinct death programmes concurrently. Normally, only the fastest and most effective death pathway is evident, but one cell may also display characteristics of several death programmes simultaneously (Bursch et al., 1996) .
Classification of PCD according to the involvement of cellular compartments
The classification of PCD based on the nuclear morphology does not take into the account the death signalling pathways involved. Therefore, attempts to sort PCD according to the cellular compartments involved in the process (mitochondria, lysosomes, plasma membrane receptors, nuclei, cytoskeleton and endoplasmic reticulum) may provide a more informative basis for the taxonomy (Ferri and Kroemer, 2001) . It does, however, not offer a simple solution, because most death pathways depend on input from several parts of the cell, the major one being the mitochondrion that is essential for the vast majority of death pathways ( Figure 1 ). As mitochondrial membrane permeabilization (MMP) is the event that defines the point of no return in most PCD models, its control and consequences are described first followed by the depiction of the involvement of other cellular compartments to MMP-dependent as well as MMP-independent PCD.
Control of MMP
The pathways upstream of MMP are numerous and with only few exceptions tightly controlled by the members of the Bcl-2 family (Figure 1 ). Bax and Bak, the 'multidomain' proapoptotic Bcl-2 family members, are crucial poreforming molecules that trigger MMP and the release of death-inducing molecules from the mitochondrial intermembrane space. Bax/Bak induce initially outer Figure 1 The control and consequences of MMP. Pore-forming proteins Bax and/or Bak can trigger MMP following activation by BH3-only proteins or cleavage. Caspase-8 and cysteine cathepsin can cleave and activate a BH3-only protein, Bid, disruption of the cytoskeleton leads to the release of BH3-only proteins Bim and Bmf, activation of the JNK pathway increases the expression Bmf and Hrk, DNA damage induces a p53-mediated transcription of genes encoding Bax, BH3-domain only proteins (Noxa and PUMA) as well as proteins involved in ROS generation, ER stress results in the release of Ca 2 þ , which may cause direct mitochondrial damage or activate Bax via calpain-mediated cleavage and hypoxia-activated transcription factor HIF-1a induces the expression of BNIP3, whose stability is increased by acidosis, and activation of CD47 releases BNIP3 from the receptor allowing it to translocate to the mitochondrial membrane. Furthermore, various death stimuli trigger the production of lipid second messengers that are involved in MMP and mitochondrial damage. Mitochondrial damage leads to the release of numerous mitochondrial proteins that trigger the execution of PCD. Cytochrome c, Smac/Diablo and Omi/Htra2 triggers caspase activation and classic apoptosis. AIF triggers a caspase-independent death pathway culminating in DNA fragmentation and stage 1 chromatin condensation characteristic of apoptosis-like PCD. Endonuclease G cleaves DNA and induces stage 2 chromatin condensation. The serine protease activity of Omi/Htra2 mediates caspase-independent cellular rounding and shrinkage without changes in the nuclear morphology. Ca 2 þ and ROS can lead into severe mitochondrial dysfunction and necrosislike PCD with or without autophagy. The schematic drawings in the bottom of the figure provide a general guideline to differentiate between the different PCD forms according to the nuclear morphology. Caspase-dependent chromatin compaction and fragmentation to crescent-or spherical-shaped masses at the nuclear periphery is shown in the middle. Caspase-independent chromatin margination triggered directly by microinjection of AIF or in a number of other models of apoptosis-like death is shown at right. No chromatin condensation, but sometimes passive clumping and dissolution of nucleoli is characteristic of necrotic PCD Cell death pathways as regulators of tumour initiation and progression M Jäättelä membrane permeability and leave the inner membrane, the protein import function and the ultrastructure of mitochondria intact (Von Ahsen et al., 2000) . Bax/Bak can be activated transcriptionally or by conformational change induced by cleavage or binding to BH3-only proteins (a subgroup of proapoptotic Bcl-2 proteins that share homology to Bcl-2 only in the Bcl-2 homology domain 3). Antiapoptotic Bcl-2 proteins (e.g. Bcl-2 and Bcl-X L ) oppose MMP presumably by heterodimerization with Bax-like proteins. In contrast, proapoptotic 'BH3-only' proteins (Bad, Bid, Bim, Bmf, Noxa, PUMA, BNIP3, etc.) either oppose the inhibitory effect of Bcl-2-like proteins via BH3-mediated binding or activate Bax-like proteins by direct binding. BNIP3, a death-promoting 'BH3-only' protein differs from the other proteins of this class. It can integrate into the mitochondrial outer membrane in a BH3-domain-and presumably also Bax/Bak-independent manner to trigger the loss of mitochondrial transmembrane potential, reactive oxygen species (ROS) generation and PCD with characteristics of autophagic degeneration (Vande Velde et al., 2000) . Similarly, overexpression of Hspin1, another Bcl-2 binding transmembrane protein with no BH3 domain, causes upregulation of a lysosomal protease cathepsin D and autophagy without release of proapoptotic proteins from the mitochondrial intermembrane space (Yanagisawa et al., 2003) . Furthermore, increase in cytosolic calcium and arachidonic acid may induce mitochondrial damage in a Bax/Bakindependent manner (Scorrano et al., 2001; Scorrano et al., 2003) .
Consequences of MMP
MMP limited to the mitochondrial outer membrane is sufficient for the release of death-promoting molecules from the mitochondrial intermembrane space, whereas permeabilization of both membranes normally results in necrosis-like PCD characterized by the loss of mitochondrial transmembrane potential and major metabolic disturbances due to the reduced ATP generation and increased production of ROS (Figure 1 ). The classical apoptosis pathway is initiated by the release of cytochrome c (Li et al., 1997) . It prompts the ATPdependent assembly of the apoptosome complex consisting of cytochrome c, apoptotic protease-activating factor 1 and caspase-9, which forms the template for efficient caspase processing and activation. As a further safe-guard mechanism, caspase-inhibitory factors (proteins of inhibitor of apoptosis protein family) have to be removed by additional proteins (Smac/Diablo or Omi/ htra2) released from mitochondria before the execution caspases can become fully active and bring forth the typically apoptotic morphology best characterized by the compact condensation of the chromatin Suzuki et al., 2001) .
Another distinct pathway following MMP is mediated by AIF (Susin et al., 1999) . Once released from the mitochondria, AIF translocates into the nucleus where it induces caspase-independent type 1 chromatin condensation by an as yet undefined mechanism. EndoG and a serine protease Omi/Htra2 may also contribute to the caspase-independent death signalling downstream of MMP. Extramitochondrial expression of Omi triggers necrosis-like PCD that is dependent on Omi's serine protease activity (Suzuki et al., 2001) , and EndoG can cause caspase-independent DNA fragmentation in isolated nuclei (Li et al., 2001) . Caenorhabditis elegans AIF ortholog (wah-1) associates and cooperates with the C. elegans EndoG ortholog (CPS-6) to promote DNA degradation and apoptosis . Whether EndoG and AIF also define a single MMP-initiated DNA degradation pathway in mammalian cells remains to be studied. Whereas there is emerging evidence suggesting that AIF may serve as a safe-guard death executioner in some cancer cells with faulty caspase activation in vitro as well as in c-Myc-induced mammary tumours in vivo (Joseph et al., 2002; Alonso et al., 2003; Liao and Dickson, 2003) , the roles of EndoG and Omi/ Htra2 in cancer cell death await to be elucidated.
Instead of the relatively rapid death pathways described above, mitochondrial damage may also lead to a slow sequestration of the damaged mitochondria in autophagic vacuoles (Tolkovsky et al., 2002) . If the damage is limited, autophagy may serve as a rescue mechanism inhibiting the further release of the deathpromoting mitochondrial proteins to the cytosol. However, in the case of more severe or continuous damage, autophagy leads to metabolic death after a lag phase of several days.
In the majority of cell death models, the master controllers of PCD operate at the mitochondrial level, whereas the decision concerning the nature of the death is taken after this step. There are, however, certain cases where mitochondria may not hold a regulatory role, but instead organelles like lysosomes and endoplasmic reticulum (ER) might be in charge of the execution of the cell (Chi et al., 1999; Elliott et al., 2000; Nylandsted et al., 2000; Sperandio et al., 2000; Inbal et al., 2002; Nylandsted et al., 2002) .
Receptor-mediated PCD comes in many shapes
Plasma membrane plays an important role in the lifedeath decisions of the cell via its numerous receptors that promote either survival or PCD. Death receptors of tumour necrosis factor receptor (TNFR) superfamily, for example TNFR1 and Fas (also known as CD95) and receptors for TNF-related apoptosis-inducing ligand (TRAIL), trigger almost the whole spectrum of different death pathways either dependent or independent of MMP and caspases and provide thus an exceptional example of the complexity of PCD signalling (Ashkenazi, 2002; Ja¨a¨ttela¨and Tschopp, 2003) . The basic signalling unit of DRs consists of three receptors, which are brought together and actived upon binding to the trimeric ligand. The receptors then assemble a deathinducing signalling complex. Through a death domainmediated binding of the adaptor proteins TRADD (TNF-R1) and FADD (all death receptors), death receptors recruit and activate the apoptosis-initiating proteases caspase-8 and/or caspase-10 that induce apoptosis either by direct activation of effector caspases or via a Bax/Bak-dependent MMP triggered by caspase-8-mediated cleavage of Bid (Luo et al., 1998; Scaffidi et al., 1998) . Another type of signalling complex induced by death receptors involves the kinase receptor-associated protein 1 (RIP1) and the caspase-8 inhibitor FLIP, which, via their interaction with TNFR-associated factors (TRAFs) links death receptors to the signalling cascades activating the NF-kB transcription factor and mitogen-activated protein kinases (Thome and Tschopp, 2001) .
Embryonic fibroblasts or thymocytes from mice deficient in FADD and caspase-8 are resistant to FasL and TNF (Varfolomeev et al., 1998; Yeh et al., 1998; Zhang et al., 1998) , revealing the central role of caspase activation and thus apoptosis in death receptor signalling. A number of recent reports show however that FasL, TNF and TRAIL cause cell death even in the absence of caspase activation in other cell types. The nonapoptotic caspase-independent PCD may even be predominant, for instance in the L929 fibrosarcoma cell line (Vercammen et al., 1998a, b) . These cells respond to TNF with necrosis-like PCD without the involvement of caspases, despite the fact that Fas-stimulation leads to caspase-dependent apoptosis. When caspases are inhibited by various means, the cells still die upon Fas stimulation, albeit with reduced efficacy, delayed kinetics and necrosis-like morphology. Thus, within the same cell line both death pathways are available to death receptors but are differentially engaged depending on the nature of the incoming signal. Since the presence of caspase inhibitors in L929 cells results not only in the appearance of a Fas-triggered necrosis, but also in a 1000-fold sensitization towards TNF-induced necrosis, caspases may be implicated in an antinecrotic pathway.
The DR-induced caspase-independent pathway is not restricted to the L929 cells. In the U937 and Jurkat leukaemia, HT29 colon carcinoma, NIH3T3 fibroblast and WEHI-S fibrosarcoma cells, caspase-independent PCD with either necrosis-or apoptosis-like morphology can be engaged by TNF, FasL and/or TRAIL (Khwaja and Tatton, 1999; Holler et al., 2000; Luschen et al., 2000; Foghsgaard et al., 2001; Wilson and Browning, 2002) . Our understanding of the signalling pathway leading to DR-induced nonapoptotic PCD and the mechanisms governing the decision points between the caspase-dependent and -independent cell death is as yet limited. FasL-induced necrotic PCD is absent in T cells that are deficient in FADD, indicating that the presence of FADD is crucial for both necrotic and apoptotic PCD induced by FasL (Holler et al., 2000) . Another protein involved in the necrotic signalling cascade is RIP1. Jurkat cells deficient in RIP1 are completely resistant to cell death even at high concentrations of FasL, provided that caspases are inhibited (Holler et al., 2000) . Unlike RIP1's function in the recruitment of the activation of NF-kB (Kelliher et al., 1998) , the kinase activity of RIP1 is indispensable for its death-promoting activity (Holler et al., 2000) . This suggests that RIP1 phosphorylates and thereby regulates a key player of the nonapoptotic cell death programme. Fas can also trigger caspase-independent apoptosis-like PCD. In immortalized epithelial cells, activated Fas recruits Daxx from the nucleus to the receptor complex and triggers its binding with apoptosis signal-regulating kinase 1 (Ask1). In addition to a caspase-dependent proapoptotic function that depends on its kinase activity, Ask1 possesses a caspase-independent killing function that is independent of its kinase activity and is activated by interaction with Daxx (Charette et al., 2001) . The relationship between RIP1-mediated and Daxx/Ask1-mediated death pathways remains to be studied.
The caspase-independent PCD triggered by TNF is mechanistically similar but not identical to that triggered by Fas. While the kinase activity of RIP1 is also obligatory, FADD appears to be dispensable (Holler et al., 2000) . Furthermore, pharmaceutical inhibition and antisense cDNA-mediated depletion of the lysosomal cysteine protease cathepsin B confers almost complete protection against TNF (and TRAIL)-induced apoptosis-like caspase-independent PCD in WEHI-S cells (Foghsgaard et al., 2001) . Consistent with the prominent role of cathepsin B in this pathway, immortalized murine embryonic fibroblasts (iMEFs) deficient for cathepsin B are highly resistant to TNF (Foghsgaard et al., 2002) . Interestingly, cathepsin Bdeficient primary MEFs display similar sensitivity to TNF as the wild-type MEFs (Foghsgaard et al., 2001 ), but upon cellular immortalization MEFs become over 1000-fold sensitized to TNF-induced apoptosis-like PCD that is cathepsin B-dependent and caspaseindependent. This sensitization is further increased upon Ras-and Src-mediated transformation of iMEFs (N Fehrenbacher and MJ, unpublished) . Whether cathepsin B is on the same pathway as RIP1 is still an open question. This is, however, supported by data showing that the treatment of Jurkat cells with TLCK, a potent inhibitor of serine and cysteine proteases including cathepsin B, inhibits RIP1-dependent necrosis-like PCD induced by TNF and FasL (Holler et al., 2000) .
There is ample evidence that excess ROS formation is involved in the nonapoptotic PCD induced by death receptors. Inhibition of caspases (which sensitizes to necrosis) results in increased ROS formation and the addition of butylated hydroxyanisole (BHA), an oxygen radical scavenger, hinders both TNF-and FasL-induced necrosis-like PCD in L929 cells and TNF-induced apoptosis-like PCD in WEHI-S cells and iMEFs (Vercammen et al., 1998b; Foghsgaard et al., 2002) . TNF-induced ROS has been proposed to be a result of enhanced electron flow through the mitochondrial electron transport chain (Schulze-Osthoff et al., 1992) . Other possible intracellular sources of ROS include lysosomes and phospholipase A2 (PLA2). Interestingly, the TNF-induced activation of PLA2 is dependent on cathepsin B (Foghsgaard et al., 2002) .
In addition to the death pathways described above, TNF-R1 triggers caspase-independent autophagy and membrane blebbing mediated by death-associated protein kinase (DAPK) and DAPK-related protein kinase 1 (DRP-1) in cells displaying caspase-mediated and DAPK/DRP1-independent nuclear fragmentation
Cell death pathways as regulators of tumour initiation and progression M Jäättelä (Inbal et al., 2002) . Interestingly, inhibition of caspases but not DAPK/DRP1 could rescue cells from death. In fact DAPK/DRP1 inhibition increased the amount of cells with condensed and fragmented nuclei, suggesting that autophagy may function as a rescue mechanism against caspase-mediated apoptosis in this model system. Other cell surface receptors that trigger alternative death pathways in a cancer-specific manner include CD20, CD47, CD99 and insulin-like growth factor 1 receptor (IGF1R). Rituximab is an anti-CD20 antibody successfully used for the treatment of lymphoma. In vitro, it induces a mitochondria-and caspase-independent exposure of phosphatidylserine and caspase-independent loss of mitochondrial membrane potential, suggesting that its efficacy may be due to the ability to kill lymphoma cells in spite of defective caspase activation or overexpression of Bcl-2-like proteins (Chan et al., 2003) . Activation of CD47, a receptor for thrombospondin, initiates necrosis-like PCD in B-cell chronic lymphoma cells (Mateo et al., 1999) . Also, resting B and T cells are affected but to a lesser degree suggesting that therapies targeting CD47 may prove useful in the clinic (Mateo et al., 2002; Lamy et al., 2003) . CD47-initiated death is characterized by early mitochondrial dysfunction, suppression of mitochondrial membrane potential and generation of ROS without signs of cytochrome c release or caspase activation. BNIP3, the Bcl-2 family protein mediating autophagy (Vande Velde et al., 2000) , may be the effector molecule in this pathway (Lamy et al., 2003) . It binds to the unoccupied receptor, but translocates to the mitochondrial membrane upon ligand or antibody binding. Furthermore, downregulation of BNIP3 with antisense oligonucletides partially attenuates CD47-induced necrotic death. Antibodies to yet another lymphoid receptor, CD99 triggers a rapid and profound apoptosis-like PCD in transformed but not normal T cells by an as yet unidentified pathway (Pettersen et al., 2001) .
Ligand-activated IGF1R mediates one of the most potent survival signals for cancer cells (Evan and Vousden, 2001 ). Overexpression of an unoccupied IGF1R or its cytosolic tail triggers, however, necrosislike death that is independent of MMP, Apaf-1 and caspase activity (Sperandio et al., 2000) . Surprisingly, this pathway is dependent on procaspase-9 protein suggesting that procaspase-9 may posses another enzymatic activity or function as an adaptor protein linking unidentified death effectors to IGF1R in order to trigger necrosis-like PCD in cells deprived of IGF. Thus, IGF1R antagonists may turn out to be more successful in cancer therapy than anticipated. Furthermore, it will be interesting to study whether other so-called dependence receptors activate a similar pathway. In the case of 'deleted in colorectal cancer' (DCC), an Apaf-1-and MMP-independent death pathway has already been described, but contrary to IGF1R, DCC-induced apoptosis is dependent on caspase activity (Forcet et al., 2001) . Activation of this pathway may, however, prove useful in treatment of cancers with defects in the mitochondrial pathway.
Lysosomes, the underestimated suicide bags
Lysosomes have until recently been considered as 'suicide bags' that through the release of unspecific enzymes cause autolysis and damage neighbouring cells during uncontrolled tissue damage. However, accumulating data now show that lysosomes also function as death signal integrators in many controlled death paradigms (Brunk et al., 2001; Ferri and Kroemer, 2001; Turk et al., 2002; Ja¨a¨ttela¨and Tschopp, 2003) (Figure 2 ). Lysosomal proteases, cathepsins, translocate from the lysosomal lumen to the cytosol in response to a wide variety of death stimuli such as TNF and TRAIL (Foghsgaard et al., 2001) , Fas (Brunk and Svensson, 1999) , p53 activation , retinoids (Zang et al., 2001) , growth factor starvation and oxidative stress (Brunk and Svensson, 1999) , B-cell receptor activation (van Eijk and de Groot, 1999), T-cell activation and staurosporine (Bidere et al., 2003) . Once released to the cytosol, cathepsins, especially cysteine cathepsins B and L and aspartyl cathepsin D, may trigger MMP followed by caspase-or AIF-mediated apoptosis (Roberg et al., 2002; Bidere et al., 2003; Boya et al., 2003; Cirman et al., 2003) . Akin to caspase-8, lysosomal cysteine cathepsins can cleave and activate Bid (Cirman et al., 2003) . Thus, Bid may function as one of the links that connects lysosomal leakage to MMP. Lysosomal leakage may also trigger mitochondrial dysfunction in a Bid-and Bcl-2-independent manner Figure 2 Lysosomal control of PCD. Lysosomal leakage is induced by the indicated stimuli by an undefined mechanism. Effector molecules released from the lysosome include cathepsins, ROS and H þ . Cathepsins released from the lysosomes function in the apoptosis pathway by causing mitochondrial membrane permeabilization via cleavage of Bid or via activation of PLA2 and the following increase in arachidonic acid (AA) level. Cathepsins may also directly cause caspase-independent chromatin condensation. Acidification of the cytosol can stabilize BNIP3 that triggers autophagy or activate L-DNase II that can cause partial chromatinolysis in a caspase-independent manner. ROS may be involved in mitochondrial damage and necrosis-like PCD (Boya et al., 2003) . Second messengers involved in such pathways may include ROS and arachidonic acid (Boya et al., 2003; Foghsgaard et al., 2002) . Cathepsins can also mediate MMP-and caspase-independent PCD with apoptosis-like morphology (Vancompernolle et al., 1998; Foghsgaard et al., 2001) . As the latter pathway can circumvent most of the known resistance mechanisms occurring in tumour cells, lysosomal membrane permeabilization appears as a promising target for cancer therapy.
Lysosomal leakage leads inevitably to intracellular acidification, whose role in lysosomal PCD has been only poorly studied. The acidification of the cytosol has, however, many consequences that may contribute to the lysosomal PCD. Firstly, acidification has been shown to trigger cJun N-terminal kinase (JNK)-mediated caspaseand Bcl-2-independent necrosis-like PCD in bladder cancer cells (Zanke et al., 1998) . Secondly, acidification can induce a post-translational modification of an antiapoptotic serine protease inhibitor, leucocyte elastase inhibitor, that converts it into L-DNase II that in turn can mediate nuclear changes typical of apoptosislike PCD (Altairac et al., 2003) . And finally, autophagyinducing Bcl-2 family member BNIP3 can be stabilized by intracellular acidification (Kubasiak et al., 2002) . Whether these mechanisms are involved in lysosomal death pathways needs to be experimentally tested, but they may explain some of the varying morphologies seen following lysosomal leakage.
Lysosomes are also crucial in the autophagic degeneration (Lockshin and Zakeri, 2002; Reggiori and Klionsky, 2002; Ogier-Denis and Codogno, 2003) . Even though autophagy can be initiated by mitochondrial damage, it does also occur in the absence of MMP, and most described forms of autophagic death are insensitive to Bcl-2. During autophagy (or macroautophagy), a portion of cytosol or cytosolic organelles are sequestered by a structure known as autophagosome that is isolated from the remaining cell contents by a double-membrane. Subsequently, the autophagosome fuses with lysosomes and the inner membrane as well as the sequestered materials are digested by lysosomal enzymes. Morphologically, autophagy is characterized by the appearance of abundant vacuoles in the cytosol and it has been described as a prominent form of PCD during development (Lockshin and Zakeri, 2002) . Of interest to cancer research, autophagy-inducing stimuli include starvation, hypoxia, radiation, antioestrogens as well as cytokines such as TNF and interferon g (Ogier-Denis and Codogno, 2003) . Moreover, emerging data suggest that autophagy may play a central role in the control of tumorigenesis (see below).
Nucleus as a death sensor
The best-defined nuclear death pathway leading to MMP and apoptosis is that triggered by DNA damage-induced activation of p53 (Vousden and Lu, 2002) . Bax and 'BH3-only' proteins Noxa and PUMA are direct target genes of p53 and gene knockout studies have revealed that they are required for efficient DNA damage-induced MMP and apoptosis (Villunger et al., 2003) . Additionally, ROS may mediate p53-induced MMP via the upregulation of genes involved in ROS generation. Recent data also suggest that p53 may serve as a link to the stress-induced direct activation of caspase-2. p53-induced death domain protein (PIDD), RAIDD (RIP-associated ICE-like death domain protein) and caspase-2 form an apoptosome-like complex capable of activating caspase-2 (J Tschopp, personal communication). The activated caspase-2 can then act as an initiator caspase and trigger MMP to amplify the caspase activation (Lassus et al., 2002) . Whether the stress-induced caspase-2 can mimic DR-activated caspase-8 and engage a lethal caspase activation cascade independent of MMP is as yet unclear.
Studies employing various pharmacological protease inhibitors suggest that also noncaspase proteases with activities resembling cysteine cathepsins (inhibited by z-FA-fmk) and possibly other cysteine or serine proteases (inhibited by TLCK) participate in p53-mediated PCD (Lotem and Sachs, 1996) . This may be explained by the recent data showing that p53 provokes an early lysosomal leakage that precedes MMP . Inhibitors of lysosomal cysteine proteases block MMP in this model, suggesting that lysosomal leakage is an early event that is necessary for the p53-induced PCD. Additionally, DNA damage induced by g irradiation, etoposide or adriamycin upregulates lysosomal aspartyl protease cathepsin D in a p53-dependent manner, and pepstatin A, a cathepsin D inhibitor, partially suppresses p53-dependent death of lymphoid cells (Wu et al., 1998) . p53-induced lysosomal leakage is not attenuated by an antioxidant implicating that ROS are not involved in this process, whereas the ability of caspase-2 and proapoptotic Bcl-2 family members to destabilize lysosomes remains to be elucidated.
In spite of their importance in respect to the treatment of human cancer, p53-independent apoptotic responses to DNA damage are poorly studied. Possible pathways involve activation of other tumour suppressor proteins; for example, interferon regulatory factor 1 (Tamura et al., 1995) , breast cancer susceptibility gene BRCA1 (Harkin et al., 1999) , p73 (Gong et al., 1999) and promyelocytic leukaemia protein (PML) . In addition to caspase-mediated apoptosis, PML can trigger a caspase-independent death programme displaying cytoplasmic apoptotic features, which are even enhanced in the presence of pan-caspase inhibitors (Quignon et al., 1998; Wang et al., 1998) . Recent results show also that DNA-damaging agents can trigger lysosomal leakage in cancer cells lacking functional p53 (J Nylandsted and MJ, unpublished) .
ER as a sensor of stress
ER is an important sensor of cellular stress and it may initiate PCD by at least two distinct mechanisms, the unfolded protein response and release of Ca 2 þ (Ferri and Kroemer, 2001 ). Both events lead eventually to MMP and may thus activate the classical apoptosis pathway as well as the other death pathways triggered by MMP. Stimuli that induce an increase in the intracellular free calcium [Ca 2 þ ] i may cause direct calcium-mediated mitochondrial and/or lysosomal damage or activate Bax via calpain-mediated cleavage (Mattson et al., 2000; Choi et al., 2001; Leist and Ja¨a¨ttela¨, 2001) . Calpains may also convert Bcl-X L to a proapoptotic MMP-inducing protein (Nakagawa and Yuan, 2000) .
Calpains are cysteine proteases that reside in the cytosol in an inactive form, and their activation requires an elevation in [Ca 2 þ ] i (Wang, 2000) . Calpain activity is controlled by calpastatin, a natural inhibitor that can be inactivated by calpain-or caspase-mediated cleavage. Calpains are activated by various stimuli (e.g. irradiation, etoposide, neurotoxins and ionophores) that increase the [Ca 2 þ ] i and they can in turn participate in PCD signalling upstream or downstream of caspases ). Furthermore, calpains mediate apoptosis-like PCD even in the absence of caspase activation. For example, EB1089, a vitamin D analogue currently in phase III clinical trials for the treatment of cancer (Mathiasen et al., 1999; as well as re-expression of a tumor suppressor gene ARHI (Bao et al., 2002) induce calpain-dependent apoptosis-like PCD in cancer cells without triggering detectable caspase activation.
Cytoskeleton and cytosol
The cytoskeleton controls MMP by binding to 'BH3-only' proteins Bim and Bmf and keeping them thereby inactive . Changes in the cytoskeleton by various cytoskeleton disrupting or stabilizing drugs or by cell detachment can thus lead to MMP and apoptosis induced by the release of Bim and Bmf. On the contrary, intact cytoskeleton is needed for autophagy to occur (Ogier-Denis and Codogno, 2003) .
Tumour cells are often challenged by hypoxia and acidosis. Hypoxia-induced factor 1a (HIF-1a) upregulates the autophagy-inducing Bcl-2 protein BNIP3 (Kothari et al., 2003) , whose expression level is further increased by acidosis-mediated stabilization (Kubasiak et al., 2002) . Accordingly, BNIP3 is expressed in hypoxic regions of tumors but fails to induce cell death presumably due to survival signalling via tyrosine kinase receptors (Kothari et al., 2003) . Notably, HIF-a also upregulates many genes involved in apoptosis resistance, metabolic adaptation, angiogenesis and metastasis making the net effect of hypoxia most likely tumour promoting (Semenza, 2003) . Furthermore, HIF-1a is overexpressed in human cancers not only due to hypoxia but also as a result of increased synthesis induced by oncogenes or decreased degradation due to loss of von Hippel-Lindau tumour suppressor protein.
Taken together, all cellular compartments appear to be equipped with sensors that can detect stressful changes in the environment and weapons to set off PCD providing a cell with multiple ways to get rid of damaged and potentially dangerous cells. Thus, tumour cells have to get rid of many enemies on their way through transformation and tumour progression.
Promotion and inhibition of PCD during tumourigenesis
The intensive apoptosis research during the last 15 years has convincingly demonstrated that the development of aggressive tumours depends on numerous defects in apoptosis signalling (Hanahan and Weinberg, 2000) . The requirement for apoptosis resistance is partially explained by the nature of cancer-associated growthpromoting signals themselves. Uncontrolled proliferative responses induced by enhanced activity of oncoproteins like c-Myc, or the inactivation of tumour suppressor proteins like retinoblastoma protein, result in a deregulated cell cycle and sustained activation of E2F-1, which can trigger caspase activation and accelerated apoptosis (Evan et al., 1992; Wu and Levine, 1994) (Table 1) . Even though growth promotion and survival functions of oncoproteins of Ras and Src families are prominent in tumours, they also carry the ability to trigger cellular senescence and apoptosis and may thus suppress transformation (Yao and Scott, 1993; Frisch and Francis, 1994; Tanaka et al., 1994; Chen et al., 1997) . Many of the stresses that a cell must encounter on its way to form an aggressive tumour (hypoxia, starvation, cytotoxic lymphocytes, DNA damage as well as detachment from the extracellular matrix and neighbouring cells) further add to the selective pressure to suppress apoptosis. To obtain net growth, growth-stimulating signals and environmental stresses must thus be coupled to reduced apoptosis potential. In line with this, human tumours harbour several inactivating mutations in proapoptotic genes and/or show increased expression or activity of antiapoptotic proteins (Table 1) . For example, mutations in proapoptotic p53 tumour suppressor gene or changes in the expression levels of its regulators are the most frequent genetic abnormalities in human cancers (Vousden and Lu, 2002) . Other common antiapoptotic alterations in cancer cells include tilted balance in the expression levels of pro-and antiapoptotic Bcl-2 family members towards the favour of the latter; growth factorindependent activation of receptor tyrosine kinases; lack of PTEN, the negative regulator of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB, also called Akt); activating mutations of PKB; inactivation of Apaf-1 in therapy-resistant melanomas; overexpression of survivin or other inhibitor of apoptosis protein family members; and increased levels of anti-apoptotic heatshock proteins (Evan and Vousden, 2001; Reed, 2001; Simpson and Parsons, 2001; Coultas and Strasser, 2003; Downward, 2003) .
Emerging evidence suggest that apoptosis is not the only lethal challenge tumour cells encounter during tumorigenesis. Transformation and tumour progression are also coupled to alternative death pathways that have to be suppressed for cancer to develop and evolve (Table 1) . For example, activating mutations of ras proto-oncogenes, the most frequently mutated protooncogenes in human tumors, trigger autophagy in glioblastoma as well as colon and gastric cancer cells (Chi et al., 1999; Pattingre et al., 2003) . The ability of Ras to cause autophagy may explain the autophagy observed in prostate cancer cells following activation of ErbB2 and ErbB3 (receptor tyroisine kinases that activate Ras pathway) (Tal-Or et al., 2003) . Interestingly, one of the signalling pathways regulated by Ras, the Raf-Erk1/2 pathway, triggers autophagy (Pattingre et al., 2003) , whereas another downstream arm of Ras signalling, PI3K-PKB pathway, inhibits it (Arico et al., 2001) . Additionally, the Ras-induced increase in the expression and trafficking of lysosomal cathepsins may contribute to Ras-induced autophagy (Roshy et al., 2003) . Cells that fail to escape autophagy by activation of PI3K-PKB pathway, may do so by inactivating mutations or depletions of genes encoding for Beclin-1, Bin-1 or death-associated protein kinase (DAPK), all proteins with tumour suppressor properties (Liang et al., 1999; Elliott et al., 2000; Ogier-Denis and Codogno, 2003) . Beclin-1 is a Bcl-2-interacting protein that has structural similarity to the yeast autophagy gene apg6/ vps30. It is monoallelically deleted in 40-75% of sporadic human breast cancers and ovarian cancers. Bin1, on the other hand, interacts with c-Myc and inhibits its transforming activity. It is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma. DAPK is a calcium-regulated serine/threonine kinase that in addition to activating the p19ARF/p53-mediated apoptotic checkpoint, is an important mediator of autophagy induced by starvation, antioestrogens, interferon g and TNF Inbal et al., 2002) . Human tumour cell lines and tumours of various origins have frequently lost DAPK expression as a result of silencing by DNA methylation . Importantly, reintroduction of Beclin-1, Bin-1 or an active form of DAPK into tumour cells that either lack them or express them in low levels triggers autophagic degeneration. Furthermore, Bcl-2, the major oncogene controlling apoptosis, can also confer protection against autophagy (Saeki et al., 2000) . Downregulation of Bcl-2 in HL60 leukaemia cells causes autophagy in a caspase-and MMP-independent manner (Saeki et al., 2000) . The cellular change triggering autophagy in these cells is not defined, but it could be related to the ability of Bcl-2 to control cellular calcium homeostasis and thereby the activation of DAPK (Lam et al., 1994) . Finally, it should be noted that autophagy does not necessarily always inhibit tumorigenesis, but it may in fact also promote it via its ability to protect against stresses associated with tumour progression, that is hypoxia, starvation and increased apoptosis (Ogier-Denis and Codogno, 2003) . Lysosomes and the control of their stability are affected in many ways during the tumorigenesis. Transformation by either Ras or Src upregulates the expression of cysteine cathepsins, increases their secretion and sensitizes cells to TNF-induced cathepsin Bdependent PCD (Roshy et al., 2003) (N Fehrenbacher and MJ, unpublished) . Accordingly, tumour progression is associated with several changes that confer resistance to the lysosomal death pathway, that is, activation of PI3K and NF-kB, increased expression of cathepsin inhibitors and Hsp70, as well as loss of p53 (Table 1) . Hsp70 chaperone protein is commonly overexpressed in human, tumours and its high expression is associated with therapy resistance and poor prognosis (Ja¨a¨ttela¨, 1999) . Even though Hsp70 is mainly known as a potent survival protein, it sensitizes cells to apoptosis induced by Fas, T-cell receptor and cytotoxic lymphocytes suggesting that its protective function rather covers nonapoptotic PCD pathways (Liossis et al., 1997; Multhoff et al., 1997) . Accordingly, the depletion of Hsp70 induces a massive caspase-independent PCD in tumour cells of various origins and experimental tumours in mice, indicating that transformation is coupled to the activation of an alternative Hsp70-controlled death pathway (Nylandsted et al., 2000; Nylandsted et al., 2002; Frese et al., 2003) . This pathway is mediated by lysosomal cysteine cathepsins that are released into the cytosol of Hsp70-depleted tumour cells before any signs of cell death are evident (J Nylandsted and MJ, unpublished) . Interestingly, Hsp70 is localized to the lysosomal membranes of cancer cells and Hsp70 positive lysosomes display increased resistance against chemical and physical membrane destabilization. Furthermore, Hsp70 expression in diverse cell types effectively inhibits TNF-and anticancer drug-induced cell death at the level of the lysosomal leakage. Thus, Hsp70 may promote tumorigenesis by stabilizing the lysosomal membrane. Also, the mechanism by which NF-kB helps cells to escape the lysosomal death was recently uncovered (Liu et al., 2003) . NF-kB induces the expression of Spi2A, a potent inhibitor of serine proteases and lysosomal cysteine cathepsins. Also, other inhibitors of noncaspase proteases may confer growth advantage to metastatic tumours that frequently express high levels of cathepsins and other proteases capable of degrading extracellular matrix (Duffy, 1996) . For example, the expression of Cystatin A in breast cancer correlates with an aggressive phenotype and adverse outcome (Kuopio et al., 1998) , and tissue inhibitor of metalloproteinases-1 rescues mammary epithelial cells from stromelysin-1-induced PCD in vivo (Alexander et al., 1996) .
Concluding remarks
Death signalling in tumour cells appears much more complex than originally suggested by the simple caspase activation model, and PCD can result in multiple morphological end points brought about by caspaseindependent mechanisms or by signalling routes utilizing caspases in combination with other effectors. Collectively, the data indicate that various forms of PCD are triggered by processes involved in transformation and tumour progression. Indeed, elimination of cells that have lost functions of important tumour suppressor proteins or bear activated oncogenes by PCD may present the primary means by which such mutant cells are continually removed from the body. The participation of alternative PCD pathways together with apoptosis in this process imposes a great challenge to the developing tumour and may explain the relative rarity of cancer in respect to the huge number of cell divisions and mutations during a human life.
